Structure of TNO155

first-in-class allosteric SHP2 phosphatase inh.

oral agent in multiple trials for cancer

from 1.5M cmpd biochemical HTS + SBDD

J. Med. Chem., Sep. 24, 2020

Novartis, Cambridge, MA

TNO155 is an allosteric inhibitor of the SHP2 phosphatase, which has been a hot target in oncology recently due to its promotion of mutant KRAS activity as well as its…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.